Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...
Hosted on MSN3h
Scientists Make Groundbreaking Discovery in the Search for the Cause of Inflammatory Bowel DiseaseIn a major breakthrough, researchers in the UK have discovered a potential root cause of inflammatory bowel disease (IBD), a ...
Technology Networks spoke with Dr. Thomas Dennison, University of Cambridge, to learn more about the advantages of using ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral ...
Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...
Medpage Today on MSN1d
Children With IBD Showed Impaired Growth Before DiagnosisChildren who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...
Zacks.com on MSN2d
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease ConditionEli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United ...
Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...
The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback